# Future Directions in Relapsed and Refractory Large B-cell Lymphoma

Page: https://stenobird.com/podcast/blood-podcast-664776/future-directions-in-relapsed-and-refractory-large-b-cell-lymphoma
Text version: https://stenobird.com/podcast/blood-podcast-664776/future-directions-in-relapsed-and-refractory-large-b-cell-lymphoma.md
Podcast: [Blood Podcast](https://stenobird.com/podcast/blood-podcast-664776)
Published: 2026-06-11T16:00:00+00:00
Episode link: https://share.transistor.fm/s/de6fdfa2
Audio file: https://prfx.byspotify.com/e/media.transistor.fm/de6fdfa2/b1e1daae.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/future-directions-in-relapsed-and-refractory-large-b-cell-lymphoma
Duration seconds: 1518

## Resource

In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “ From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma ”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/future-directions-in-relapsed-and-refractory-large-b-cell-lymphoma/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/blood-podcast-664776/future-directions-in-relapsed-and-refractory-large-b-cell-lymphoma.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.